New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
08:11 EDTADHDAlcobra completes patient recruitment in Phase III clinical trial of MDX
Alcobra announced that recruitment of patients has been completed in the company's Phase III clinical trial of Metadoxine Extended Release, or MDX, in adult ADHD patients. The study is a 300-patient, randomized, placebo-controlled trial conducted at 18 sites in the United States and 2 in Israel. Patients were randomized to receive either 1400 mg MDX or placebo over 6 weeks following a 2-week screening period. The primary endpoint is the Conners' Adult ADHD Rating Scale, or CAARS-INV, a widely accepted clinical measure of the presence and severity of ADHD symptoms. Secondary endpoints include the computerized TOVA, or Test of Variables of Attention, which was also used in the previous Phase 2 studies, as well as safety assessments and additional exploratory endpoints.
News For ADHD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
13:34 EDTADHDAlcobra volatility elevated into Phase III trial data
Alcobra October call option implied volatility is at 477, November is at 349, December is at 283; compared to its 15-week average of 193 according to Track Data, suggesting large price movement into release of data from the first Phase III trial of MDX in Adult ADHD.
10:32 EDTADHDOptions with increasing implied volatility
Subscribe for More Information
06:06 EDTADHDStocks with implied volatility above IV index mean; SNSS ADHD
Subscribe for More Information
September 30, 2014
06:02 EDTADHDStocks with implied volatility above IV index mean; SNSS ADHD
Subscribe for More Information
September 26, 2014
06:07 EDTADHDStocks with implied volatility above IV index mean; SNSS ADHD
Stocks with implied volatility above IV index mean; Sunesis (SNSS) 329, Alcobra (ADHD) 334 according to iVolatility.
September 23, 2014
10:37 EDTADHDAlcobra October volatility elevated into Phase III trial data
Alcobra October call option implied volatility is at 347, November is at 249, December is at 223; compared to its 15-week average of 191 according to Track Data, suggesting large price movement into release of data from the first Phase III trial of MDX in Adult ADHD.
September 22, 2014
07:12 EDTADHDAlcobra October volatility elevated into Phase III trial data
Subscribe for More Information
September 19, 2014
16:24 EDTADHDAlcobra announces completion of all patient visits in phase 3 MDX trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use